To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients with nasopharyngeal carcinoma (NPC).
To relate pretreatment plasma EBV DNA concentration to WHO classification of these tumors both in endemic and non-endemic areas.
To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for both endemic and non-endemic patient populations.
Enrollment
49 patients
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
Having a new diagnosis of Nasopharyngeal carcinoma.
Being treated with either radiotherapy or chemoradiotherapy for this condition.
Exclusion criteria
Age <18 since NPC is a very rare condition in this age group and may have a different biological behavior
Patients who are unable to provide informed consents for themselves.